HR
ALNY icon

Howe & Rusling’s Alnylam Pharmaceuticals ALNY Stock Holding History

Howe & Rusling’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-400
Closed -$21K – 944
2017
Q1 		$21K Sell
400
-600
-60% -$27.7K ﹤0.01% 357
2016
Q4 		$37K Buy
1,000
+400
+67% +$16.7K 0.01% 294
2016
Q3 		$41K Buy
600
+400
+200% +$28.2K 0.01% 278
2016
Q2 		$11K Buy
+200
New +$12.6K ﹤0.01% 457

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Howe & Rusling's ALNY Position: Q2 2017 in Review

Howe & Rusling sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 400 shares — an estimated $21K sold.

Howe & Rusling first reported a position in ALNY in Q2 2016 and held it in 4 quarters. The position peaked at $41K in Q3 2016. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

  • Howe & Rusling reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Howe & Rusling sold 400 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $21K.
  • Howe & Rusling first reported a position in Alnylam Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Howe & Rusling's Alnylam Pharmaceuticals position peaked at $41K in Q3 2016.
  • 227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Howe & Rusling's 13F filing for Q2 2017, filed 13 Jul 2017.